Publications

  1. et. al. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology 1(6), 449-458.
  2. & Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology 19(11), 1480-1492.
  3. et. al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine 373(19), 1803-1813.
  4. et. al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine 377(14), 1345-1356.
  5. et. al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine

See more...

Teaching

  • PM-317 Genetics of Cancer

    This module will provide students with an advanced understanding about the genetic mechanisms involved in carcinogenesis, and how these underlying processes and molecules affect the human body.